Cargando…

Development and Validation of the Test of Orthorexia Nervosa (TON-17)

This study aims to develop and validate a new self-report questionnaire to measure orthorexia nervosa (ON). Based on a current review of the scientific literature and interviews with people at risk of orthorexia, 40 items were selected to test orthorexia nervosa (TON-40). A total sample of 767 indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogowska, Aleksandra M., Kwaśnicka, Aleksandra, Ochnik, Dominika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069172/
https://www.ncbi.nlm.nih.gov/pubmed/33921511
http://dx.doi.org/10.3390/jcm10081637
_version_ 1783683174826508288
author Rogowska, Aleksandra M.
Kwaśnicka, Aleksandra
Ochnik, Dominika
author_facet Rogowska, Aleksandra M.
Kwaśnicka, Aleksandra
Ochnik, Dominika
author_sort Rogowska, Aleksandra M.
collection PubMed
description This study aims to develop and validate a new self-report questionnaire to measure orthorexia nervosa (ON). Based on a current review of the scientific literature and interviews with people at risk of orthorexia, 40 items were selected to test orthorexia nervosa (TON-40). A total sample of 767 individuals (M = 26.49, SD = 9.66, 56.98% women) participated in the study. The exploratory factor analysis (EFA), confirmatory factor analysis (CFA), and composite construct analysis (CCA) were performed to find an appropriate model of sufficient reliability and validity and stable construction. Convergent validation was performed regarding the correlation of the TON-17 with another measure of ON (ORTO-15), eating disorders (the EAT-26 and DEAS), healthy behavior (the HBI), quality of life (the Brief WHOQOL), physical health (the GRSH), anxiety (the GAD-7), depression (the PHQ-9), and obsessive-compulsive disorder (the OCI-R). Gender, Body Mass Index (BMI), and the medical reasons for a restrictive diet were also examined. As a result of the structural analyses, the number of items was reduced from 40 to 17. The best fit indices of the TON-17 were found for the hierarchical bi-factor model, with three lower-order factors (Control of food quality, Fixation of health and healthy diet, and Disorder symptoms) and one general higher-order factor (Orthorexia). According to the 95th percentile method of estimation, the prevalence of ON was 5.5% for the TON-17 total score. The TON-17 scale and subscales showed good psychometric properties, stability, reliability, and construct validity. The TON-17 indicated a positive relationship with the ORTO-15, EAT-26, DEAS, HBI, OCI-R, GAD-7, and PHQ-9. TON-17 can be considered as a useful tool for assessing the risk of ON.
format Online
Article
Text
id pubmed-8069172
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80691722021-04-26 Development and Validation of the Test of Orthorexia Nervosa (TON-17) Rogowska, Aleksandra M. Kwaśnicka, Aleksandra Ochnik, Dominika J Clin Med Article This study aims to develop and validate a new self-report questionnaire to measure orthorexia nervosa (ON). Based on a current review of the scientific literature and interviews with people at risk of orthorexia, 40 items were selected to test orthorexia nervosa (TON-40). A total sample of 767 individuals (M = 26.49, SD = 9.66, 56.98% women) participated in the study. The exploratory factor analysis (EFA), confirmatory factor analysis (CFA), and composite construct analysis (CCA) were performed to find an appropriate model of sufficient reliability and validity and stable construction. Convergent validation was performed regarding the correlation of the TON-17 with another measure of ON (ORTO-15), eating disorders (the EAT-26 and DEAS), healthy behavior (the HBI), quality of life (the Brief WHOQOL), physical health (the GRSH), anxiety (the GAD-7), depression (the PHQ-9), and obsessive-compulsive disorder (the OCI-R). Gender, Body Mass Index (BMI), and the medical reasons for a restrictive diet were also examined. As a result of the structural analyses, the number of items was reduced from 40 to 17. The best fit indices of the TON-17 were found for the hierarchical bi-factor model, with three lower-order factors (Control of food quality, Fixation of health and healthy diet, and Disorder symptoms) and one general higher-order factor (Orthorexia). According to the 95th percentile method of estimation, the prevalence of ON was 5.5% for the TON-17 total score. The TON-17 scale and subscales showed good psychometric properties, stability, reliability, and construct validity. The TON-17 indicated a positive relationship with the ORTO-15, EAT-26, DEAS, HBI, OCI-R, GAD-7, and PHQ-9. TON-17 can be considered as a useful tool for assessing the risk of ON. MDPI 2021-04-12 /pmc/articles/PMC8069172/ /pubmed/33921511 http://dx.doi.org/10.3390/jcm10081637 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rogowska, Aleksandra M.
Kwaśnicka, Aleksandra
Ochnik, Dominika
Development and Validation of the Test of Orthorexia Nervosa (TON-17)
title Development and Validation of the Test of Orthorexia Nervosa (TON-17)
title_full Development and Validation of the Test of Orthorexia Nervosa (TON-17)
title_fullStr Development and Validation of the Test of Orthorexia Nervosa (TON-17)
title_full_unstemmed Development and Validation of the Test of Orthorexia Nervosa (TON-17)
title_short Development and Validation of the Test of Orthorexia Nervosa (TON-17)
title_sort development and validation of the test of orthorexia nervosa (ton-17)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069172/
https://www.ncbi.nlm.nih.gov/pubmed/33921511
http://dx.doi.org/10.3390/jcm10081637
work_keys_str_mv AT rogowskaaleksandram developmentandvalidationofthetestoforthorexianervosaton17
AT kwasnickaaleksandra developmentandvalidationofthetestoforthorexianervosaton17
AT ochnikdominika developmentandvalidationofthetestoforthorexianervosaton17